Change of lot or extension of reference standard shelf-life is considered low risk and should be downgraded from prior-approval to being managed in the Pharmaceutical Quality System (PQS) only based on a science and risk-based approach.
Julie Barthuet
Advertisement
Julie Barthuet is head Regulatory CMC&D Vaccines at Sanofi Vaccines.
Articles by Julie Barthuet
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
5